Pathologic response to predict survival in patients who underwent surgery after neoadjuvant chemotherapy with bevacizumab for clinical stage II/IIIA non-squamous non-small cell lung cancer.

被引：0
|
作者：
Tsutani, Yasuhiro
Kai, Yuichiro
Ito, Masaoki
Mimura, Takeshi
Miyata, Yoshihiro
Suzuki, Kenji
Takamochi, Kazuya
Tanaka, Fumihiro
Nakayama, Haruhiko
Yamashita, Yoshinori
Oda, Makoto
Tsuboi, Masahiro
Okada, Morihito
机构：
[1] Hiroshima Univ, Hiroshima, Japan
[2] Juntendo Univ, Sch Med, Tokyo, Japan
[3] Juntendo Univ, Tokyo, Japan
[4] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan
[5] Kanagawa Canc Ctr, Kanagawa, Japan
[6] Chugoku Canc Ctr, Dept Gen Thorac Surg, Kure Med Ctr, Hiroshima, Japan
[7] Kanazawa Univ, Kanazawa, Ishikawa, Japan
[8] Natl Canc Ctr Hosp East, Div Thorac Surg, Kashiwa, Chiba, Japan
[9] Hiroshima Univ Hosp, Hiroshima, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e20023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20023
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pathologic response and survival after cisplatin, pemetrexed, and bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer
    Tsutani, Y.
    Miyata, Y.
    Suzuki, K.
    Takamochi, K.
    Tanaka, F.
    Nakayama, H.
    Yamashita, Y.
    Oda, M.
    Tsuboi, M.
    Okada, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Neoadjuvant chemotherapy with bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer: Survival results from a phase II feasibility study (NAVAL)
    Tsutani, Y.
    Miyata, Y.
    Suzuki, K.
    Takamochi, K.
    Tanaka, F.
    Nakayama, H.
    Yamashita, Y.
    Oda, M.
    Tsuboi, M.
    Okada, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] A phase II feasibility study of preoperative chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer.
    Miyata, Yoshihiro
    Tsutani, Yasuhiro
    Suzuki, Kenji
    Takamochi, Kazuya
    Tanaka, Fumihiro
    Nakayama, Haruhiko
    Yamashita, Yoshinori
    Tsuboi, Masahiro
    Oda, Makoto
    Okada, Morihito
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL)
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Suzuki, Kenji
    Tanaka, Fumihiro
    Ito, Hiroyuki
    Yamashita, Yoshinori
    Okada, Morihito
    CANCERS, 2024, 16 (13)
  • [5] Efficacy and safety of bevacizumab and platinum-based chemotherapy as neoadjuvant regimen for stage-IIIA non-squamous non-small cell lung cancer: A retrospective study
    Jiang, Dexiong
    Rao, Yao
    Zhang, Chunxi
    Wang, Dan
    Jiang, Xu
    Wang, Huachuan
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [6] Chemotherapy and surgery in stage IIIa non-small cell lung cancer
    Skarin, Arthur T.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (06) : 577 - 578
  • [7] Plasma VEGF level after bevacizumab plus chemotherapy treatment is associated with the survival of patients with non-squamous non-small cell lung cancer
    An, She-Juan
    Wu, Yi-Long
    Xu, Chong-Rui
    Chen, Jian-Guang
    Yang, Yan
    Zhou, Hai-Yu
    CANCER RESEARCH, 2009, 69
  • [8] Neoadjuvant Combination Sintilimab plus Chemotherapy in Patients with Resectable Stage IIIA Non-Small Cell Lung Cancer.
    Ma, K.
    Sun, C.
    Jia, X.
    Wang, X.
    Xu, Y.
    Guo, Y.
    Qiu, S.
    Shao, G.
    Zhang, P.
    Liu, Y.
    Ma, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S650
  • [9] Clinical efficacy of bevacizumab combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer
    Liu, Yuhua
    Mao, Aihong
    Ma, Qin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (07): : 9049 - 9057
  • [10] Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non-small cell lung cancer.
    Ferrer, Loic
    Nadal, Ernest
    Guidel, Floriane
    Insa, Amelia
    Menu, Philippe
    Casal, Joaquin
    Domine, Manuel
    Massuti, Bartomeu
    Majem, Margarita
    Martinez-Marti, Alex
    Garcia Campelo, Rosario
    de Castro Carpeno, Javier
    Cobo, Manuel
    Vivanco, Guillermo Lopez
    del Barco, Edel
    Bernabe, Reyes
    Vinolas, Nuria
    Barneto, Isidoro
    Colin, Thierry
    Provencio-Pulla, Mariano
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345